Biotechnology Buyers & Acquisitions in Maryland

Tracked deals

11

11 tracked deals across 2019-2026.

Buyer mix

Strategic-led

11 strategic

Top trend

Volume peaked in 2021

4 tracked deals announced in 2021.

Buyer Snapshot

Top Buyers

Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.

Build a buyer list for your Biotechnology deal →
Buyer # Deals Focus Type
BiomX Inc. 1 Clinical-stage biotechnology company developing natural a... Strategic
Catalent, Inc. 1 Global provider of advanced delivery technologies and dev... Strategic
Charles River Laboratories International, Inc. 1 Global provider of preclinical, clinical laboratory and c... Strategic
Eli Lilly and Company 1 Large global pharmaceutical company with vaccine and drug... Strategic
Merck 1 Global, research-intensive pharmaceutical company develop... Strategic
Neon Bloom, Inc. 1 Publicly traded company (OTC: NBCO) focused on cannabis/h... Strategic
Nephros, Inc. 1 Water technology company providing filtration and pathoge... Strategic
SK bioscience 1 Global vaccine and biotech company focused on vaccine R&D... Strategic
STEMCELL Technologies 1 Developer and supplier of specialized reagents, cell cult... Strategic
Smiths Detection 1 Global provider of threat detection and screening technol... Strategic

Acquisition Volume in Biotechnology in Maryland by Year

Last 5 years

Acquisition volume by year Annual acquisition counts for the last 5 years for Biotechnology Buyers & Acquisitions in Maryland. 1 2019 2 2020 4 2021 3 2024 ~2 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion
    May 27, 2026
    Buyer
    Eli Lilly and Company
    Target
    Vaccine Company, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

  • SK bioscience Invests $3M in U.S. Biotech Fina Biosolutions
    October 8, 2024
    Buyer
    SK bioscience
    Target
    Fina Biosolutions (FinaBio)
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Growth capital

    SK bioscience has invested USD 3 million to acquire a stake in Fina Biosolutions (FinaBio), a Rockville, Maryland–based developer of conjugate vaccine technologies and CRM197 protein manufacturing. The strategic investment makes SK bioscience FinaBio's first strategic investor and is intended to accelerate commercialization of FinaBio's EcoCRM and conjugation technologies while enhancing SK bioscience's vaccine development and manufacturing capabilities.

  • BiomX Acquires Adaptive Phage Therapeutics
    March 18, 2024
    Buyer
    BiomX Inc.
    Target
    Adaptive Phage Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.

  • STEMCELL Technologies Acquires Propagenix Inc.
    January 19, 2024
    Buyer
    STEMCELL Technologies
    Target
    Propagenix Inc.
    Seller
    Propagenix co-founders
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    STEMCELL Technologies, Canada’s largest biotechnology company, acquired Propagenix Inc., a Gaithersburg, Maryland biotechnology firm focused on epithelial cell biology and its patented EpiX technology. The acquisition includes Propagenix’s assets, IP (including its Conditional Reprogramming license with Georgetown University) and existing business arrangements, enabling STEMCELL to develop EpiX-based products for clinical applications and expand its regenerative-medicine capabilities.

  • Vaccitech plc Acquires Avidea Technologies to Expand SNAPvax Pipeline
    December 13, 2021
    Buyer
    Vaccitech plc
    Target
    Avidea Technologies, Inc.
    Seller
    Avidea's existing shareholders
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Vaccitech plc acquired US-based Avidea Technologies, Inc. for approximately $40 million (about $12.5M cash and $27.5M in Vaccitech ADS) plus potential milestone payments. The deal brings Avidea's SNAPvax™ nanoparticle platform and early-stage product candidates into Vaccitech's pipeline, expands Vaccitech's U.S. R&D presence, and adds Avidea co-founders to Vaccitech's scientific team.

  • Nephros Acquires Substantially All Assets of GenArraytion, Inc.
    July 12, 2021
    Buyer
    Nephros, Inc.
    Target
    GenArraytion, Inc.
    Seller
    GenArraytion, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Nephros, Inc. (Nasdaq: NEPH) acquired substantially all of the assets of GenArraytion, Inc., a Rockville, Maryland-based developer of infectious disease PCR assays and multiplexing technology. The acquisition gives Nephros access to GenArraytion's MultiFLEX bioassays and other proprietary assays, which will be integrated into Nephros' Pathogen Detection Systems platform, and GenArraytion's CEO Dr. R. Paul Schaudies will partner with Nephros' pathogen detection leadership.

  • Charles River Laboratories Acquires Vigene Biosciences
    May 17, 2021
    Buyer
    Charles River Laboratories International, Inc.
    Target
    Vigene Biosciences, Inc.
    Seller
    Signet Healthcare Partners
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

  • Neon Bloom, Inc. Acquires Bazelet Health Systems, Inc.
    March 18, 2021
    Buyer
    Neon Bloom, Inc.
    Target
    Bazelet Health Systems, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Neon Bloom, Inc. (OTC: NBCO) has completed an all-stock acquisition of 100% of Bazelet Health Systems, Inc., issuing 120,000,000 Neon Bloom common shares. The deal brings Bazelet’s plant science, CRISPR-based genome engineering capabilities and accredited cannabis education business under Neon Bloom to accelerate research, commercialization and expansion in the legal cannabis/hemp and life‑sciences markets.

  • Merck Acquires OncoImmune
    November 23, 2020
    Buyer
    Merck
    Target
    OncoImmune
    Seller
    OncoImmune shareholders
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Merck will acquire all outstanding shares of clinical-stage biopharmaceutical OncoImmune for $425 million upfront in cash, with additional sales-based and regulatory milestone payments possible. The deal centers on accelerating development of OncoImmune’s CD24Fc for severe and critical COVID-19; non-CD24Fc assets will be spun out into a new company in which Merck will invest $50 million for a minority stake.

  • Smiths Detection Acquires PathSensors
    August 4, 2020
    Buyer
    Smiths Detection
    Target
    PathSensors
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Smiths Detection has completed the acquisition of PathSensors, a Baltimore-based biotechnology and environmental-testing company. The deal expands Smiths Detection's biological-detection capabilities, enhancing its ability to detect pathogens across end markets including food and agriculture safety and public health surveillance.

  • Catalent Acquires Paragon Bioservices for $1.2 Billion
    May 20, 2019
    Buyer
    Catalent, Inc.
    Target
    Paragon Bioservices, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.

Build a buyer list for your Biotechnology deal

Find buyers actively acquiring biotechnology companies.

Apply as a Buyer

Related Acquisition Pages

Biotechnology Buyers & Acquisitions Biotechnology Buyers & Acquisitions in Canada Private Equity-Backed Biotechnology Buyers Biotechnology Acquisitions in 2026 Biotechnology Acquisitions in 2024 Biotechnology Acquisitions in 2021 Biotechnology Acquisitions in 2020 Biotechnology Acquisitions in 2019 Acquisitions in Maryland Private Equity-Backed Acquisitions in Maryland Acquisitions in Maryland in 2026 Acquisitions in Maryland in 2024